Replies to post #20832 on Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

The Provista/Radient merger you are quoting was cancelled several years ago. Today, Provista is not involved, in ANY way, with Radient.

But by all means, prove your case. Please tell us the patent number for even ONE Provista patent that involves Radient, DR-70, onko-sure, MacLellan, or CIT in ANY way.

The USPTO system is easy to search. I've done a lot of patent searches. I only see one existing patent for DR-70, and it expires in six weeks. I only see ONE patent pending for DR-70, and it was rejected, then resubmitted in Feb 2013 as an RCE, and currently sits in the RCE backlog queue. Research that I have posted several times shows that an RCE submitted in 2013 will not be reviewed for at least three years after submission. That's Feb 2016.

[lakeshore555]

That LOI for the Radient/Provista merger in 2010 described Provista becoming a subsidiary of Radient.

in 2010, it looked like Radient had $20 million shareholder equity, with new financing just completed. Provista was smaller and had fewer assets.

Fast forward to today. Radient has a huge shareholder deficit because that $20 million equity was Jade and the SEC forced Radient to admit in 2011 that Jade was worth nothing. Radient defaulted not only on the 2010 loans but the 2011 loans as well. Radient today has no facility or even an office and has no assets.

Provista, meanwhile, did some financing of their own, built a huge new facility, and today is successfully operating.

For that 2010 LOI to be "enforceable" or "in force" or whatever, that means Provista is still going to become a subsidiary of Radient.

Not likely, in my opinion.